- ALung Technologies, Inc. is now part of LivaNova
May 2, 2022 – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, has been acquired by LivaNova and will be part of its Advanced Circulatory Support business unit. For more information on LivaNova, please visit www.livanova.com.
- FDA Grants the Hemolung® De Novo Clearance
PITTSBURGH – (BUSINESS WIRE) – November 15, 2021 – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced that the Food and Drug Administration (FDA) has granted the Company De Novo
- FDA Grants ALung Emergency Use Authorization (EUA) to the ALung for the Treatment of COVID-19
PITTSBURGH – (BUSINESS WIRE) – April 24, 2020 – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced that the Food and Drug Administration (FDA) has granted the Company Emergency Use
- ALung Announces Commercial Development of its Breakthrough Next Generation Artificial Lung
PITTSBURGH–(BUSINESS WIRE)– April 4, 2020 – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the recent initiation of commercial development of its next generation artificial lung, which expands the Company’s
- ALung Announces that the Independent Data and Safety Monitoring Board (DSMB) Recommends Continuation of VENT-AVOID Trial and Reports that Significant Progress Continues with their Clinical Trial Programs
PITTSBURGH – (BUSINESS WIRE) – May 9, 2019 – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the achievement of a major milestone in its U.S. based VENT-AVOID clinical